Enhanced SIA-chemiluminescence probes for angiotensin II receptor antagonist detection using silver and gold nanoparticles: applications in pharmaceutical formulations

2018 ◽  
Vol 42 (5) ◽  
pp. 3383-3393 ◽  
Author(s):  
N. A. Alarfaj ◽  
S. A. Altamimi ◽  
M. F. El-Tohamy ◽  
A. M. Almahri
Keyword(s):  
Gold Nanoparticles ◽  
Angiotensin Ii ◽  
Receptor Antagonist ◽  
Candesartan Cilexetil ◽  
Pharmaceutical Formulations ◽  
Sequential Injection ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Silver And Gold Nanoparticles

The present work describes three different sequential injection chemiluminescence systems for the detection of some angiotensin II receptor antagonists, such as candesartan cilexetil, valsartan and telmisartan.

scholarly journals Long-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
K. Wegleiter ◽  
M. Waltner-Romen ◽  
R. Trawoeger ◽  
U. Kiechl-Kohlendorfer ◽  
E. Griesmaier
Keyword(s):  
Angiotensin Ii ◽  
Receptor Antagonist ◽  
Neonatal Period ◽  
Clinical Symptoms ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Receptor Antagonists

Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high. Despite this well-known risk potential, a considerable number of women still receive angiotensin II receptor antagonists during pregnancy to treat arterial hypertension. Although clinical symptoms in the neonatal period are well described, few reports address long-term follow-up after fetal exposure to angiotensin II receptor antagonists. We here report on a patient who was unwittingly exposed to olmesartan medoxomil during pregnancy. After birth, the neonate presented with mild clinical symptoms, mainly affecting the kidneys. However, neurodevelopmental follow-up revealed a delay in motor development with muscular hypotonia and failure to thrive at age 2 years. This case highlights the fact that, despite not causing neurological symptoms in the neonatal period, fetal angiotensin II receptor antagonist exposure during pregnancy might lead to neurodevelopmental impairment in later life.

scholarly journals Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan

2011 ◽  
Vol 17 (4) ◽  
pp. 325-332 ◽  
Author(s):  
Y. V. Sviryaev ◽  
N. E. Zvartau
Keyword(s):  
Angiotensin Ii ◽  
Cardiovascular Diseases ◽  
Receptor Antagonist ◽  
Antihypertensive Effect ◽  
Clinical Use ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Receptor Antagonists

The article focuses on antihypertensive effect, organoprotection properties and clinical use of angiotensin II receptor antagonist valsartan in patients with cardiovascular diseases.

Sign in / Sign up

Export Citation Format

Share Document